Cargando…
POSC41 Cost-Effectiveness Analysis of Remdesivir for the Treatment of COVID-19 Hospitalized Adults in Mexico
Autores principales: | Ponce-de-León, A, Azamar-Alonso, A, Silva-Sanchez, F, Chirino-Sprung, R, Dominguez-Esquivel, V, Rajme-López, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769609/ http://dx.doi.org/10.1016/j.jval.2021.11.446 |
Ejemplares similares
-
EE410 Cost-Effectiveness Analysis of Remdesivir for the Treatment of COVID-19 Hospitalized Adults in Three Countries of LATAM: Argentina, Chile, and Colombia
por: Montejano, R, et al.
Publicado: (2022) -
POSC102 High-Flow Nasal Cannula in Patients with COVID-19: Is a Cost-Effective Alternative?
por: Alves Junior, JM, et al.
Publicado: (2022) -
POSC65 Cost-Benefit Analysis of Ready-to-Administer Noradrenaline for Hypotensive Emergency on Intensive Care
por: Griffin, E, et al.
Publicado: (2022) -
POSC254 The Impact of COVID-19 on European HTA Decisions
por: Watson, C, et al.
Publicado: (2022) -
POSC243 Systemic Challenges in Tele-Health and Structural Solutions to Enhance Access
por: Johnson, P.A., et al.
Publicado: (2022)